 Connection
Thomas Jensen to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Thomas Jensen has written about Diabetes Mellitus, Type 2.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.330 |
|
|
|
-
Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, Kitzman DW, Møller DV, Treppendahl MB, Verma S, Jensen TJ, Liisberg K, Lindegaard ML, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovský V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Shah SJ. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024 04 18; 390(15):1394-1407.
Score: 0.079
-
Kobo O, Cavender MA, Jensen TJ, Kuhlman AB, Rasmussen S, Verma S. Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis. Diabetes Obes Metab. 2024 Mar; 26(3):1129-1132.
Score: 0.077
-
Crowley MJ, McGuire DK, Alexopoulos AS, Jensen TJ, Rasmussen S, Saevereid HA, Verma S, Buse JB. Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. Diabetes Care. 2020 09; 43(9):e108-e110.
Score: 0.061
-
Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB. Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. Diabetes Care. 2018 08; 41(8):1663-1671.
Score: 0.053
-
Jensen TJ, Hilsted JC. [Pharmacological prevention of late complications of diabetes]. Ugeskr Laeger. 1996 Apr 22; 158(17):2402-3.
Score: 0.045
-
Hansen CN, Jensen TJ, Borch-Johnsen K. [Dyslipidemia, diabetes and cardiovascular disease]. Ugeskr Laeger. 2000 Aug 14; 162(33):4367-70.
Score: 0.015
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|